Glioma

EDITORIAL
Year
: 2018  |  Volume : 1  |  Issue : 1  |  Page : 1-

Preface from Editor-in-Chief


Zhong-Ping Chen 
 Department of Neurosurgery/Neuro-oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China

Correspondence Address:
Dr. Zhong-Ping Chen
Department of Neurosurgery/Neuro-oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong
China




How to cite this article:
Chen ZP. Preface from Editor-in-Chief.Glioma 2018;1:1-1


How to cite this URL:
Chen ZP. Preface from Editor-in-Chief. Glioma [serial online] 2018 [cited 2023 Jan 29 ];1:1-1
Available from: http://www.jglioma.com/text.asp?2018/1/1/1/226435


Full Text

It is with great excitement that we announce the establishment of the journal Glioma, a bimonthly publication devoted to the neuro-oncology field, with a particular focus on glioma. As readers, you may wonder with several neuro-oncology journals already in existence, why did we still want to create Glioma?

Gliomas are the most frequent primary tumors of the central nervous system. However, despite the extensive research around the world on effective treatment strategies, the prognosis of glioma patients remains unsatisfactory. With advances in basic research and scientific technologies, novel therapeutic options demonstrate great potential in improving the treatment outcomes of glioma patients. There has been a rapid emergence of breakthroughs in glioma-related research, and these findings are being published in a wide range of journals, not just neuro-oncology journals. Our hope is that Glioma may provide a specific platform for discussion and communication among basic scientists and clinicians.

As an official journal launched by the Chinese Society of Neuro-Oncology, our aim is to not only connect the people working in this field within China but also reach out to global scientific communities. We sincerely welcome clinicians and researchers to submit their high-quality work to us. Being an online open access journal, we will definitely provide an easier and faster communication for the fields.

We anticipate that the launching of Glioma will be a great opportunity to bring together researchers in this field to collaborate together to fight this challenging disease and improve patient care.